24/7 Market News Snapshot 03 October, 2025 – Ovid Therapeutics Inc. Common Stock (NASDAQ:OVID)

October 3, 2025

DENVER, Colo., 03 October, 2025 (www.247marketnews.com) – (NASDAQ:OVID) are discussed in this article.
Ovid Therapeutics Inc. (NASDAQ:OVID), a pioneering biopharmaceutical firm focused on innovative small molecule medicines for neurological and neuropsychiatric disorders, has recently experienced a notable surge in its stock price, currently trading at $2.067, reflecting a 26.04% increase from the previous close of $1.640. This surge is underpinned by a robust trading volume of 5.99 million shares, indicating significant investor interest and positioning Ovid as an appealing prospect in the biotech sector.

Simultaneously, Ovid has also announced a strategic private investment in public equity (PIPE) financing aimed at raising up to $175 million, with an initial close expected to secure approximately $81 million. This financing arrangement, anticipated to close on October 6, 2025, is set to include shares of Series B non-voting convertible preferred stock and accompanying warrants, which could lead to the conversion into 57,722,000 shares of common stock.

This financing initiative has garnered support from prominent investors, including Janus Henderson Investors, RA Capital Management, and Eventide Asset Management, affirming strong confidence in Ovid’s potential to address significant unmet medical needs. The capital generated will be directed towards advancing the company’s research and development projects, covering general corporate expenditures, and enhancing working capital, effectively setting the stage for long-term growth.

Ovid Therapeutics is focusing its resources on its promising pipeline, including its OV4071 candidate, with the objective of delivering transformative therapies to patients. With a solid financial foundation expected to sustain operations into 2028, Ovid is well-positioned to further its mission of improving patient outcomes in the realm of brain health. The current stock performance combined with the new financing framework highlights a significant opportunity for investment and growth within the company.

Related news for (OVID)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.